Akers Biosciences sets up Kenya deal, predicts profit
This article was originally published in Clinica
In common with many of its healthcare counterparts, point of care diagnostics producer Akers Biosciences has seen its share price under pressure this year. Since its AIM launch in London in May 2002 (see Clinica No 1008, p 14), the US company's price has slipped from an opening 135p ($2.10) to 53p. CEO Ray Akers, on a visit to London last week, told Clinica: "We're not alone in experiencing declining share prices."